MwanzoATYR • NASDAQ
add
aTyr Pharma Inc
$ 0.77
Baada ya Saa za Kazi:(1.27%)+0.0097
$ 0.78
Imefungwa: 11 Des, 19:34:51 GMT -5 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 0.82
Bei za siku
$ 0.76 - $ 0.82
Bei za mwaka
$ 0.64 - $ 7.29
Thamani ya kampuni katika soko
74.62M USD
Wastani wa hisa zilizouzwa
3.26M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | elfu 190.00 | — |
Matumizi ya uendeshaji wa biashara | 4.80M | 44.03% |
Mapato halisi | -25.74M | -49.16% |
Kiwango cha faida halisi | elfu -13.55 | — |
Mapato kwa kila hisa | -0.26 | -13.04% |
EBITDA | -26.58M | -47.95% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 90.20M | 36.70% |
Jumla ya mali | 106.65M | 16.41% |
Jumla ya dhima | 26.61M | 0.49% |
Jumla ya hisa | 80.04M | — |
hisa zilizosalia | 97.99M | — |
Uwiano wa bei na thamani | 1.00 | — |
Faida inayotokana na mali | -64.23% | — |
Faida inayotokana mtaji | -74.40% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -25.74M | -49.16% |
Pesa kutokana na shughuli | -20.48M | -55.62% |
Pesa kutokana na uwekezaji | -20.38M | -213.55% |
Pesa kutokana na ufadhili | 29.62M | 28,306.67% |
Mabadiliko halisi ya pesa taslimu | -11.24M | -339.93% |
Mtiririko huru wa pesa | -10.67M | -64.55% |
Kuhusu
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
Ilianzishwa
1 Jan 2005
Tovuti
Wafanyakazi
61
